Cargando…

A prospective study of endothelial activation biomarkers, including plasma angiopoietin-1 and angiopoietin-2, in Kenyan women initiating antiretroviral therapy

BACKGROUND: HIV-1-related inflammation is associated with increased levels of biomarkers of vascular adhesion and endothelial activation, and may increase production of the inflammatory protein angiopoietin-2 (ANG-2), an adverse prognostic biomarker in severe systemic infection. We hypothesized that...

Descripción completa

Detalles Bibliográficos
Autores principales: Graham, Susan M, Rajwans, Nimerta, Tapia, Kenneth A, Jaoko, Walter, Estambale, Benson BA, McClelland, R Scott, Overbaugh, Julie, Liles, W Conrad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3679794/
https://www.ncbi.nlm.nih.gov/pubmed/23734875
http://dx.doi.org/10.1186/1471-2334-13-263
_version_ 1782273018091798528
author Graham, Susan M
Rajwans, Nimerta
Tapia, Kenneth A
Jaoko, Walter
Estambale, Benson BA
McClelland, R Scott
Overbaugh, Julie
Liles, W Conrad
author_facet Graham, Susan M
Rajwans, Nimerta
Tapia, Kenneth A
Jaoko, Walter
Estambale, Benson BA
McClelland, R Scott
Overbaugh, Julie
Liles, W Conrad
author_sort Graham, Susan M
collection PubMed
description BACKGROUND: HIV-1-related inflammation is associated with increased levels of biomarkers of vascular adhesion and endothelial activation, and may increase production of the inflammatory protein angiopoietin-2 (ANG-2), an adverse prognostic biomarker in severe systemic infection. We hypothesized that antiretroviral therapy (ART) initiation would decrease endothelial activation, reducing plasma levels of ANG-2. METHODS: Antiretroviral-naïve Kenyan women with advanced HIV infection were followed prospectively. Endothelial activation biomarkers including soluble intercellular adhesion molecule-1 (ICAM-1), vascular adhesion molecule-1 (VCAM-1), and E-selectin, and plasma ANG-2 and angiopoietin-1 (ANG-1) were tested in stored plasma samples from 0, 6, and 12 months after ART initiation. We used Wilcoxon matched-pairs signed rank tests to compare endothelial activation biomarkers across time-points, generalized estimating equations to analyze associations with change in log(10)-transformed biomarkers after ART initiation, and Cox proportional-hazards regression to analyze associations with mortality. RESULTS: The 102 HIV-1-seropositive women studied had advanced infection (median CD4 count, 124 cells/μL). Soluble ICAM-1 and plasma ANG-2 levels decreased at both time-points after ART initiation, with concomitant increases in the beneficial protein ANG-1. Higher ANG-2 levels after ART initiation were associated with higher plasma HIV-1 RNA, oral contraceptive pill use, pregnancy, severe malnutrition, and tuberculosis. Baseline ANG-2 levels were higher among five women who died after ART initiation than among women who did not (median 2.85 ng/mL [inter-quartile range (IQR) 2.47–5.74 ng/mL] versus median 1.32 ng/mL [IQR 0.35–2.18 ng/mL], p = 0.01). Both soluble ICAM-1 and plasma ANG-2 levels predicted mortality after ART initiation. CONCLUSIONS: Biomarkers of endothelial activation decreased after ART initiation in women with advanced HIV-1 infection. Changes in plasma ANG-2 were associated with HIV-1 RNA levels over 12 months of follow-up. Soluble ICAM-1 and plasma ANG-2 levels represent potential biomarkers for adverse outcomes in advanced HIV-1 infection.
format Online
Article
Text
id pubmed-3679794
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36797942013-06-13 A prospective study of endothelial activation biomarkers, including plasma angiopoietin-1 and angiopoietin-2, in Kenyan women initiating antiretroviral therapy Graham, Susan M Rajwans, Nimerta Tapia, Kenneth A Jaoko, Walter Estambale, Benson BA McClelland, R Scott Overbaugh, Julie Liles, W Conrad BMC Infect Dis Research Article BACKGROUND: HIV-1-related inflammation is associated with increased levels of biomarkers of vascular adhesion and endothelial activation, and may increase production of the inflammatory protein angiopoietin-2 (ANG-2), an adverse prognostic biomarker in severe systemic infection. We hypothesized that antiretroviral therapy (ART) initiation would decrease endothelial activation, reducing plasma levels of ANG-2. METHODS: Antiretroviral-naïve Kenyan women with advanced HIV infection were followed prospectively. Endothelial activation biomarkers including soluble intercellular adhesion molecule-1 (ICAM-1), vascular adhesion molecule-1 (VCAM-1), and E-selectin, and plasma ANG-2 and angiopoietin-1 (ANG-1) were tested in stored plasma samples from 0, 6, and 12 months after ART initiation. We used Wilcoxon matched-pairs signed rank tests to compare endothelial activation biomarkers across time-points, generalized estimating equations to analyze associations with change in log(10)-transformed biomarkers after ART initiation, and Cox proportional-hazards regression to analyze associations with mortality. RESULTS: The 102 HIV-1-seropositive women studied had advanced infection (median CD4 count, 124 cells/μL). Soluble ICAM-1 and plasma ANG-2 levels decreased at both time-points after ART initiation, with concomitant increases in the beneficial protein ANG-1. Higher ANG-2 levels after ART initiation were associated with higher plasma HIV-1 RNA, oral contraceptive pill use, pregnancy, severe malnutrition, and tuberculosis. Baseline ANG-2 levels were higher among five women who died after ART initiation than among women who did not (median 2.85 ng/mL [inter-quartile range (IQR) 2.47–5.74 ng/mL] versus median 1.32 ng/mL [IQR 0.35–2.18 ng/mL], p = 0.01). Both soluble ICAM-1 and plasma ANG-2 levels predicted mortality after ART initiation. CONCLUSIONS: Biomarkers of endothelial activation decreased after ART initiation in women with advanced HIV-1 infection. Changes in plasma ANG-2 were associated with HIV-1 RNA levels over 12 months of follow-up. Soluble ICAM-1 and plasma ANG-2 levels represent potential biomarkers for adverse outcomes in advanced HIV-1 infection. BioMed Central 2013-06-04 /pmc/articles/PMC3679794/ /pubmed/23734875 http://dx.doi.org/10.1186/1471-2334-13-263 Text en Copyright © 2013 Graham et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Graham, Susan M
Rajwans, Nimerta
Tapia, Kenneth A
Jaoko, Walter
Estambale, Benson BA
McClelland, R Scott
Overbaugh, Julie
Liles, W Conrad
A prospective study of endothelial activation biomarkers, including plasma angiopoietin-1 and angiopoietin-2, in Kenyan women initiating antiretroviral therapy
title A prospective study of endothelial activation biomarkers, including plasma angiopoietin-1 and angiopoietin-2, in Kenyan women initiating antiretroviral therapy
title_full A prospective study of endothelial activation biomarkers, including plasma angiopoietin-1 and angiopoietin-2, in Kenyan women initiating antiretroviral therapy
title_fullStr A prospective study of endothelial activation biomarkers, including plasma angiopoietin-1 and angiopoietin-2, in Kenyan women initiating antiretroviral therapy
title_full_unstemmed A prospective study of endothelial activation biomarkers, including plasma angiopoietin-1 and angiopoietin-2, in Kenyan women initiating antiretroviral therapy
title_short A prospective study of endothelial activation biomarkers, including plasma angiopoietin-1 and angiopoietin-2, in Kenyan women initiating antiretroviral therapy
title_sort prospective study of endothelial activation biomarkers, including plasma angiopoietin-1 and angiopoietin-2, in kenyan women initiating antiretroviral therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3679794/
https://www.ncbi.nlm.nih.gov/pubmed/23734875
http://dx.doi.org/10.1186/1471-2334-13-263
work_keys_str_mv AT grahamsusanm aprospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy
AT rajwansnimerta aprospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy
AT tapiakennetha aprospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy
AT jaokowalter aprospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy
AT estambalebensonba aprospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy
AT mcclellandrscott aprospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy
AT overbaughjulie aprospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy
AT lileswconrad aprospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy
AT grahamsusanm prospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy
AT rajwansnimerta prospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy
AT tapiakennetha prospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy
AT jaokowalter prospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy
AT estambalebensonba prospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy
AT mcclellandrscott prospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy
AT overbaughjulie prospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy
AT lileswconrad prospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy